Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Barriers To Insulin Initiation And Intensification And How To Overcome Them
T. Kunt, F. Snoek
Published 2009 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Aims: To review published evidence and clinical experience of the perceived barriers to insulin initiation and intensification and to develop solutions for patient management.
This paper references
Trends in A1C concentrations among US adults with diagnosed diabetes from
E S Ford (1999)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study Group (1998)
BRIEF REPORT: The burden of diabetes therapy
S. Vijan (2007)
Trends in A1C concentrations among US adults with diagnosed diabetes
ES Ford (1999)
Switching from NPH insulin to once‐daily insulin detemir in basal–bolus‐treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study
S. Sreenan (2008)
Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes
F. Snoek (2007)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1998)
['How to convince people with type 2 diabetes to start with insulin? Treatment options for patients with psychological insulin resistance'].
E. Kuestner (2008)
Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.
W. Polonsky (2005)
Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004.
Earl S. Ford (2008)
Trends in A 1 C concentrations among US adults with diagnosed diabetes from 1999 to 2004
ES Ford (2008)
Impact of Pay for Performance on Ethnic Disparities in Intermediate Outcomes for Diabetes: A Longitudinal Study
C. Millett (2009)
The usage of a simplified self‐titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study
L. Meneghini (2007)
Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens.
S. Vijan (2005)
Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude.
T. Wallace (2000)
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
International Diabetes Federation. Global Guideline for Type 2 Diabetes
Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes
Jerry D Meece (2006)
Exploring the world mythology of diabetes
T. Dunning (2004)
Initiation of Insulin Treatment after 70 Years of Age: Patient Status 2 Years Later
F. Elgrably (1991)
This paper is referenced by
Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review
R. Goldenberg (2014)
An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes
P. Home (2015)
Study of type 2 diabetes management among patients in a Macau primary care setting
I. Wong (2019)
The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.
P. Weiden (2015)
Changes in health services usage associated with insulin initiation in primary care.
S. Johnson (2018)
Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study
D. Eton (2012)
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
H. Yki–Järvinen (2015)
Participants’ experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4‐T) trial: qualitative interview study
N. Jenkins (2011)
Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).
Siddharth Shah (2013)
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
S. Gough (2016)
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
I. Lingvay (2016)
Expectations about insulin therapy, perceived insulin‐delivery system social acceptability, and insulin treatment satisfaction contribute to decreases in insulin therapy self‐efficacy in patients with type 2 diabetes after 36 weeks insulin therapy (2型糖尿病患者经过36周的胰岛素治疗后，患者对胰岛素治疗的期望、感知的胰岛素给药装置的社会接受性以及对
R. Hayes (2013)
Barbados Insulin Matters (BIM) study: Perceptions on insulin initiation by primary care doctors in the Caribbean island of Barbados.
C. Taylor (2017)
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
N. Freemantle (2015)
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
L. Berard (2018)
Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin
K. van Brunt (2016)
The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries
K. Khunti (2012)
FACTORS THAT DRIVE INSULIN DOSING DECISIONS MADE BY DIABETES CARE PROVIDERS: A VIGNETTE STUDY IN THE NETHERLANDS
Airin C. R. Simon (2013)
Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
Mie Tonoike (2019)
Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy
D. Owens (2017)
Is DegluDec the InsulIn of tomorrow?
N. Thomas (2012)
Characteristics and practicalities of a new basal insulin.
Susan Stockley (2014)
Use of medicines and devices by adults in the management of Type 2 diabetes in Kuwait
Z. Alsairafi (2016)
Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study
J. Yale (2013)
Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: The insulin‐changing study intending to gain patients' insights into insulin treatment with patient‐reported health outcomes in actual clinical treatments (INSIGHTs) study
H. Ishii (2013)
Insulin therapy attitudes and beliefs of physicians in Middle Eastern Arab countries.
Najla Lakkis (2013)
Organic consequences of ileal transposition in rats with diet-induced obesity
Paolo H. B. Lourenco (2011)
Insulin initiation status of primary care physicians in Turkey, barriers to insulin initiation and knowledge levels about insulin therapy: A multicenter cross-sectional study.
E. Ates (2017)
Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis
Paraskevi Liakopoulou (2017)
A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes.
T. Forst (2020)
Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study
A. Nicolucci (2011)
Tilburg University Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life . A prospective cohort study in primary care
Tibor R S Hajós (2011)See more